Abbott Archives - Page 4 of 34 - Medical Design Sourcing

Abbott teams up with NFL player Damar Hamlin for ‘HeartMates Program’

Damar Hamlin and Dr. Nadim Geloo promote the HeartMates Program. [Image courtesy of Abbott]Abbott (NYSE: ABT) + today announced a new initiative to help those impacted by heart conditions with Buffalo Bills safety Damar Hamlin.

With this announcement, Hamlin becomes the first ambassador for the Abbott HeartMates Program. The program aims to create a community of support for people and caregivers impacted by heart conditions. It enables the sharing of stories and provides emotional support while connecting people with others going through similar journeys.

Hamlin in January collapsed on the field, going into cardiac arrest after making a tackle in an NFL game. He received CPR, automated external defibrillation (AED) and other treatments before being transported to the hospital. Hamlin later confirmed he suffered an episode of commotio cordis. He since made his return to the football field only a few weeks ago.

̶…

Stereotaxis performs first surgical robot procedure with Abbott cardiac mapping tech

Stereotaxis (NYSE:STXS) today announced the first treated patients in the U.S. as part of its surgical robotics collaboration with Abbott (NYSE: ABT) + .

In May, the two companies entered a deal aimed at taking robotic electrophysiology to the next level. It sought to integrate the Abbott EnSite X EP 3D heart mapping system — with Stereotaxis’ robotic magnetic navigation systems. The collaboration combines real-time diagnostic information with the precision and stability of surgical robotics.

Physicians across four U.S. medical centers completed the first integrated procedures in the U.S. They took place at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center.

Dr. Dhanunjaya Lakkireddy of Overland took part in the initial cases. Lakkireddy said in a news release that the combination of technologies enhanced precision and streaml…

How Abbott developed an accessible, affordable CGM — the FreeStyle Libre system

The FreeStyle Libre 3 reader with the sensor and smartphone. [Image courtesy of Abbott]According to Abbott Diabetes DVP, Technical Operations, Marc Taub, one in nine people in the U.S. live with diabetes.

Speaking at DeviceTalks West in Santa Clara, California, he said that means everyone in the room at the time knows someone with diabetes. The condition requires constant attention and management, something Taub and Abbott aim to alleviate.

“Diabetes is a chronic disease and it’s hard to manage,” Taub said. “It requires a person’s round-the-clock care to manage. At Abbott, it’s our mission to create life-changing technology to help make it easier for people to live better lives.

“In this case, to make it much easier for them to better manage their diabetes.”

Today, Abbott is one of the market leaders in the diabetes space with its continuous glucose monitoring (CGM) technology. It continues updating its…

The biggest cardiovascular stories from TCT 2023

Every year, some of the biggest names in cardiovascular technologies come together in one place for TCT.

This year’s 35th edition of the Transcatheter Cardiovascular Therapeutics annual scientific symposium was no different in San Francisco.

Usual suspects like Medtronic and Abbott released data covering a range of products, while other big names like Edwards, GE HealthCare and more had positive updates on their own technologies.

Last year’s TCT event highlighted some significant trends in the cardiovascular space. Let’s see what this year’s symposium brought.

Abbott’s TriClip, MitraClip shine along with drug-eluting stent

Results from Abbott’s TRILUMINATE pivotal trial reinforced the safety and effectiveness of the TriClip system. Abbott also shared data from the MitraClip EXPAND G4 real-world registry at TCT 2023.

TriClip, a transcatheter edge-to-edge repair (TEER) system, treats patients with symptomat…

What’s next for Abbott’s cardiovascular business?

Abbott (NYSE: ABT) + boosted its vascular device offerings even more with its acquisition of Cardiovascular Systems this year.

Wondering what comes next? Abbott Vascular President Julie Tyler will explain at our DeviceTalks West event, Oct. 18–19 in Santa Clara. (Register here.)

Even as COVID-19 test sales continue to decline and hammer overall revenue, Abbott officials are betting on a productive, innovative pipeline to build momentum — especially in its medical device business. In a keynote interview on the morning of Oct. 18, Tyler will discuss the company’s product platform, innovation process, and what’s to come after the acquisition of Cardiovascular Systems.

How can the merger with Cardiovascular Systems enable Abbott to better help people with vascular diseases?

Find out more at DeviceTalks West.

State of the industry — Execs ‘more bullish than ever’ on medtech

From left: Kevin Lobo, Lisa Earnhardt, Deepak Nath, Bernard Zovighian. All spoke about the state of the industry at The MedTech Conference.

Ernst & Young’s 2023 Pulse of the Industry medical technology report may not have been overly positive, but medtech executives certainly are.

The EY report highlighted sluggish revenues and post-COVID-19 corrections leading to a growth decline. In fact, it was the lowest growth in medtech since 2015. Roughly half of medtech stock price gains realized in 2021 were wiped out by the end of 2022.

However, leading medtech executives, including Stryker CEO Kevin Lobo, only see upwards.

“I feel as bullish as I’ve ever felt in my time in medtech,” Lobo declared.

Lobo, Abbott EVP of Medical Devices Lisa Earnhardt, Smith+Nephew CEO Deepak Nath and Edwards CEO Bernard Zovighian all have positive outlooks for the space. They outlined their views on a panel based around the EY report Monday at T…

Cardinal Health CEO becomes one of medtech’s top-paid executives

Cardinal Health disclosed pay and perks for other leaders and its median employee, as well as severance payouts for two former top executives.

Cardinal Health CEO Jason Hollar [Photo courtesy of Cardinal Health]

Cardinal Health paid CEO Jason Hollar nearly $18.8 million in his first year on the job, the device manufacturer and pharmaceutical distrbutor said in a new executive pay disclosure.

That makes Hollar — who was Cardinal Health’s chief financial officer until his promotion in September 2022 — the second-highest-paid CEO among the world’s largest medical device manufacturers.

Abbott CEO Robert Ford is the top-paid CEO of all medical device manufacturers at $21.7 million in total compensation. Like Cardinal Health, Abbott also has a major pharmaceutical business, but Abbott does not disclose pay for Medical Devices EVP Lisa Earnhardt.

Hollar’s total compensation for fiscal 2…

Abbott study says FreeStyle Libre users on insulin show lower HbA1c levels

The FreeStyle Libre 2 continuous glucose monitor (CGM). [Image from Abbott]Abbott (NYSE: ABT) + today announced real-world data associating its FreeStyle Libre CGM with significant HbA1c reductions.

The continuous glucose monitor (CGM) played a part in significant reductions in HbA1c, the average glucose levels over a three-month period. It was also associated with a lower rate of hospitalization for people with type 2 diabetes on both multiple daily injection (MDI) and once-daily (basal) insulin therapy.

Abbott presented its findings from the study at the 59th Annual European Association for the Study of Diabetes (EASD) in Hamburg, Germany. The comparative study from the Swedish National Diabetes Register indicates CGM’s effectiveness in type 2 diabetes management.

Get the full story at our sister site, Drug Delivery Business News.

Abbott: Real-world data indicates GLP-1s could be accelerator for FreeStyle Libre

The FreeStyle Libre 3 reader with the sensor and smartphone. [Image courtesy of Abbott]New real-world data from Abbott (NYSE: ABT) + demonstrates a potentially positive impact of GLP-1 drugs on diabetes technology.

GLP-1 receptor agonists, like Ozempic and Wegovy, provide therapy for diabetes and weight loss. This therapeutic class, a glucagon-like peptide 1, has proven to lead to improved blood sugar control and weight loss.

The drug class continues to grow in popularity and raise questions in medtech around just how large its impact could be.

Positive clinical results for GLP-1s led to recent negative market movement for a few of the biggest names in diabetes technology. Analysts reacted by cutting some forecasts on sales to reflect increased pressure thanks to the GLP-1 updates. Insulet and Embecta noted the drug’s impact in their most recent quarterly earnings. GLP-1s even had an impact on Intuitive Surgi…

Abbott completes Bigfoot Biomedical acquisition

The Bigfoot Unity platform, now acquired by Abbott. [Image courtesy of Bigfoot Biomedical]Abbott (NYSE:ABT) announced today that it completed its previously announced acquisition of Bigfoot Biomedical.

Pursuant to the terms of the merger agreement, upon completion, Bigfoot became a wholly-owned subsidiary of Abbott. The companies declined to disclose financial terms.

Abbott announced on Sept. 5 that it entered into a definitive agreement to acquire the smart insulin management company. Their longstanding relationship dates back to 2017, with the medtech giant even leading a financing round for Bigfoot in 2020.

Get the full story at our sister site, Drug Delivery Business News.

Abbott, WeightWatchers unveil connected diabetes app

The FreeStyle Libre 2, part of the integrated offering with WeightWatchers. (Image courtesy of Abbott)

Abbott (NYSE: ABT) + and WeightWatchers today announced the availability of a connected app for people living with diabetes.

In August 2022, the companies announced a collaboration to integrate continuous glucose monitoring (CGM) with the WW diabetes-tailored plan. The integrated offering provides a mobile experience with information and insights needed for those with diabetes. It helps to make healthy adjustments to their diet, improve their glucose levels and gain more control of their health.

The app helps people with diabetes understand how food and activity impact their glucose levels. WeightWatchers members who follow the tailored plan can now access their glucose data from the Abbott FreeStyle Libre 2 CGM. This all works within their WW app while under guidance from the WW diabetes-tailored plan.

Abbott recalls neurostimulation implants for Bluetooth bricking flaw

Abbott’s Proclaim XR 5 IPG Model 3660 and the Patient Controller app. (Image from Abbott)

Abbott (NYSE: ABT) + has recalled more than 155,000 implantable pulse generators (IPGs) due to a Bluetooth connectivity flaw that has left some devices unusable.

The Class I recall — the FDA’s most serious level — covers Proclaim and Infinity IPGs used for three kinds of neurostimulation:

Spinal cord stimulation: Proclaim XR 5 IPG Model 3660 (previously known as the Proclaim 5 Elite IPG Model 3660), Proclaim XR 7 IPG Model 3662 (previously known as the Proclaim 7 Elite IPG Model 3662), Proclaim Plus 5 IPG Model 3670, and Proclaim Plus 7 IPG Model 3672 Dorsal root ganglion stimulation: Proclaim DRG IPG Model 3664 Deep brain stimulation: Infinity 5 IPG Model 6660 and Infinity 7 IPG Model 6662

These devices were distributed in the U.S. between Nov. 21, 2015 and to June 29, 2023. The FDA said 186 incidents and 73 injuri…